Published in J Clin Oncol on August 01, 2005
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol (2014) 1.88
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist (2008) 1.85
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist (2008) 1.14
Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol (2009) 1.14
Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int (2008) 1.08
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol (2008) 1.05
A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One (2011) 1.03
Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol (2012) 0.90
Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology (2009) 0.89
The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas. Front Physiol (2016) 0.86
Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens. J Korean Med Sci (2011) 0.85
Robotic-assisted laparoscopic prostatectomy. Br J Cancer (2009) 0.83
Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate (2010) 0.82
Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006. Prev Chronic Dis (2011) 0.82
Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World J Urol (2011) 0.77
Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat (2010) 0.76
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. Prostate Int (2016) 0.75
Can we preoperatively identify men who are at high risk for aggressive prostate cancer? Nat Clin Pract Urol (2005) 0.75
Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence. Int J Clin Oncol (2014) 0.75
Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram. World J Urol (2010) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Improving marginal likelihood estimation for Bayesian phylogenetic model selection. Syst Biol (2010) 4.32
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 2.85
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Combination of Foley bulb and vaginal misoprostol compared with vaginal misoprostol alone for cervical ripening and labor induction: a randomized controlled trial. Obstet Gynecol (2013) 2.67
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol (2010) 2.35
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Serial biopsy results in prostate cancer screening study. J Urol (2002) 2.30
A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet (2012) 2.29
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst (2003) 2.26
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol (2004) 2.15
Interval from loop electrosurgical excision procedure to pregnancy and pregnancy outcomes. Obstet Gynecol (2013) 2.15
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Terminal fetal heart decelerations and neonatal outcomes. Obstet Gynecol (2013) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Missing data in clinical studies: issues and methods. J Clin Oncol (2012) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Association of hemospermia with prostate cancer. J Urol (2004) 1.98
Normal progress of induced labor. Obstet Gynecol (2012) 1.93
Natural history of placenta previa in twins. Obstet Gynecol (2012) 1.93
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem (2004) 1.85
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol (2007) 1.77
Single umbilical artery and its associated findings. Obstet Gynecol (2010) 1.76
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer (2007) 1.70
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int (2012) 1.68
Choosing among partition models in Bayesian phylogenetics. Mol Biol Evol (2010) 1.66
Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res (2014) 1.65
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer (2008) 1.65
Bayesian analysis for generalized linear models with nonignorably missing covariates. Biometrics (2005) 1.65
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology (2010) 1.64
What to do with an abnormal PSA test. Oncologist (2008) 1.62
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol (2008) 1.62
Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology (2009) 1.62
Under diagnosis and over diagnosis of prostate cancer. J Urol (2007) 1.61
PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 1.61
Congenital uterine anomalies and adverse pregnancy outcomes. Am J Obstet Gynecol (2011) 1.60
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol (2011) 1.58
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys (2009) 1.55
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol (2011) 1.52
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol (2011) 1.51
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology (2006) 1.51
Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer (2007) 1.50
Association of atypical decelerations with acidemia. Obstet Gynecol (2012) 1.50
Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys (2006) 1.50
Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy. BJU Int (2012) 1.47
Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet (2006) 1.46
Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol (2008) 1.46
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46